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Abstract
Background:  this study set out to examine the effects of the treatment with 1,25-
dihydroxyvitamin D3 (1,25D3) [150 IU/Kg (3.75 μg/Kg) one a day, for 15 days] to non-diabetic rats
and in rats rendered diabetic by a single injection of streptozotocin [65 mg/kg].
Results: treatment with 1,25D3 to non-diabetic rats did not affect the biochemical parameters
measured in the plasma and urine of these animals. Likewise, insulin receptor expression in the
kidney, liver, or adipose tissue and insulin-stimulated glucose transport in adipocytes from these
animals were not affected either. Treatment with 1,25D3 to streptozotocin-induced diabetic rats
did not correct the hyperglycemia, hypoinsulinemia, glycosuria or ketonemia induced by the
diabetes, although it partially reversed the over-expression of the insulin receptor gene in the liver
and adipose tissue, without altering the normal expression of this gene in the kidney. These effects
were accompanied by a normalization of the number of insulin receptors without altering receptor
affinity but improving the insulin response to glucose transport in adipocytes from these diabetic
animals. Moreover, a computer search in the rat insulin receptor promoter revealed the existence
of two candidate vitamin D response element (VDRE) sequences located at -256/-219 bp and -653/
-620 bp, the first overlapped by three and the second by four AP-2-like sites.
Conclusion: these genomic actions of 1,25D3 could represent beneficial effects associated with
the amelioration of diabetes via mechanisms that possibly involve direct transcriptional activation
of the rat insulin receptor gene. The candidate VDREs identified may respond to 1,25D3 via
activation of the vitamin D receptor, although this remains to be investigated.
Background
It is known that vitamin D and especially its activated
metabolite 1,25-dihydroxyvitamin D3  (1,25D3), are
involved in controlling the normal function of the endo-
crine pancreas, and particularly insulin secretion [1,2].
Vitamin D deficiency inhibits rat pancreatic secretion and
turnover of insulin, leading to impaired glucose tolerance,
while replacement therapy with 1,25D3, is able to reverse
these abnormalities [3,4]. 1,25D3 also affects the insulin
receptor (IR), the protein to which insulin must bind to
carry out its multiple biological actions in the cells. In this
respect, our group has reported the first demonstration
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that  1,25D3 increased human IR mRNA levels, the IR
number, and the insulin response in U-937 human prom-
onocytic cells through mechanisms that involve direct
transcriptional activation of the human IR gene [5-7].
In non-obese diabetic mice, vitamin D deficiency acceler-
ates type 1 diabetes [8], while chronic administration of
1,25D3 reduces the incidence of diabetes in these mice,
principally by modulating immune mechanisms [9-11].
Streptozotocin-induced diabetes is another animal model
of diabetes that comprises both toxic and inflammatory
mechanisms [12]. Mononuclear infiltration and the
altered morphology of islets coupled with the disappear-
ance of beta cells are among the histological changes
reported in the pancreas of these animals [12,13]. Indeed,
hyperglycemia and hypoinsulinemia, have also been
described in this experimental model [14,15]. This
hypoinsulinemia was associated with increased insulin
binding in the kidney [16,17] and liver [14,18] and with
somewhat controversial insulin binding results in adipose
tissue [15,19,20]. The increases in renal and hepatic IRs,
were accompanied by elevated IR mRNA expression in
both tissues, and it could be reversed by treatment with
insulin [21-23]. Despite the different alterations in IR
mRNA levels and insulin binding, streptozotocin-induced
diabetic rats characteristically display insulin resistance
[15,18,19]. In this diabetic model, the administration of
1,25D3 for 8 weeks was reported to improve diabetes
attenuating pancreatic islet damage and decreasing the
insulin requirements [12].
1,25D3 acts in its genomic effects as a ligand for the vita-
min D receptor (VDR, NR1I1) [24]. This receptor is a
member of the superfamily of nuclear receptors that regu-
lates gene expression as a vitamin D-dependent transcrip-
tion factor. It exerts this action by binding, preferentially
as a heterodimer with the retinoid × receptor (RXR), to
vitamin D response elements (VDREs) in the promoter
regions of target genes [25]. A VDRE generally consists of
two direct imperfect repeats of six nucleotides separated
by a three-nucleotide spacer. The VDR occupies the 3'
half-site, while the RXR binds to the 5' half-site [26].
Sequence variations have been detected in the 3' half-ele-
ment, the 5' half-element, the spacer, and in the sequences
flanking the VDREs and these variations appear to be
important in receptor-binding efficiency [27,28]. The
identification of VDREs has only been possible in a very
limited number of vitamin D-regulated genes [26,27].
Our group has reported the first identification of a func-
tional VDRE overlapped by a downstream AP-2-like site
that specifically binds VDR in the human IR gene pro-
moter [29]. This VDRE accounted for the transcriptional
induction of this gene by 1,25D3 in U-937 human cells
[7,29].
With these antecedents, the aim of the present investiga-
tion was to study the effects of the treatment with 1,25D3
[150 IU/Kg (3.75 μg/Kg) one a day, for 15 days] to non-
diabetic and streptozotocin-induced diabetic rats. The
results indicated that while treatment with 1,25D3 had
practically no effect on non-diabetic rats, the same treat-
ment in streptozotocin-induced diabetic rats corrected in
part the over-expression of the IR gene in liver and adi-
pose tissue, although it did not revert the hyperglycemia,
hypoinsulinemia, glycosuria or ketonemia of these dia-
betic animals. At the same time, it produced normaliza-
tion of the IR number without alterations in the receptor
affinity and with an improvement of the insulin response
in terms of glucose transport in isolated adipocytes of
these diabetic animals. In addition, a computer search in
the rat insulin receptor gene promoter revealed the exist-
ence of two DNA sequences: -256/-219 bp and -653/-620
bp, the first overlapped by three and the second by four
AP-2-like sites. These sequences represent two candidate
VDREs that could respond to 1,25D3 via activation of
VDR, although this remains to be further investigated.
Table 1: Body weights and plasma values of the four groups of rats under study
Control 1,25D3 STZ STZ + 1,25D3
Final weight (g) 283 ± 1 290 ± 2a 242 ± 6ab 254 ± 3abc
Glucose (mg/dl) 125 ± 7 130 ± 2 420 ± 36ab 459 ± 16ab
Insulin (ng/ml) 1.6 ± 0.3 1.5 ± 0.2 0.7 ± 0.3ab 0.5 ± 0.1ab
25-Hydroxy-vitamin D3 (ng/ml) 19 ± 1 15 ± 1 15 ± 3 17 ± 3
Calcium (mg/dl) 7.5 ± 1 10 ± 1 10 ± 0.4 11 ± 1a
Phosphorus (mg/dl) 6.8 ± 1 8.7 ± 1 7.2 ± 0.5 11 ± 0.7ac
Proteins (mg/dl) 65 ± 1 66 ± 1 63 ± 0.9 64 ± 1
Sham-treated rats (Control), rats treated with 1,25D3 [150 IU/Kg (3.75 μg/Kg) one a day, for 15 days] (1,25D3), streptozotocin-induced diabetic rats 
(STZ) and streptozotocin-induced diabetic rats treated with 1,25D3 (STZ+1,25D3).
Values are the mean ± SEM of 6–12 determinations in each group.
a p < 0.05 vs. Control-rats; b p < 0.05 vs. 1,25D3-rats; c p < 0.05 vs. STZ-rats.BMC Molecular Biology 2008, 9:65 http://www.biomedcentral.com/1471-2199/9/65
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Results
Body weights and plasma values of glucose, insulin, 25-
hidroxyvitamin D3, calcium, phosphorus and proteins
Treatment with 1,25D3 to non-diabetic rats increased the
rat body weights but did not affect any parameter in the
plasma of these animals (Table 1). The injection of strep-
tozotocin reduced body weights and induced hyperglyc-
emia and hypoinsulinemia (Table 1). Treatment with
1,25D3 to streptozotocin-induced diabetic rats increased
body weights but did not revert the hyperglycemia and the
hypoinsulinemia induced by the diabetes, while calcium
and phosphorus plasma levels were increased and plasma
levels of 25-hydroxyvitamin D3 were maintained in the
normal range [30] (Table 1).
Values of specific gravity, pH, leukocytes, nitrite, protein, 
glucose, ketones, urobilinogen, bilirubin and blood in urine
Treatment with 1,25D3 to non-diabetic rats did not affect
any of the above cited urine parameters under study.
Streptozotocin injection induced glycosuria (> 500 mg/
dl) and the appearance of leukocytes, ketones and blood
in the urine of these animals. Treatment with 1,25D3to
streptozotocin-induced diabetic rats did not modify the
glycosuria and the ketonuria of the diabetes, but partially
decreased the number of leukocytes in urine (from 10–25
to 5–10 leukocytes/μl).
Total DNA, RNA and protein content of the kidney, liver 
and epididymal adipose tissue
Treatment with 1,25D3 to non-diabetic rats increased both
the protein content and the indicator of cell size (protein/
DNA) in the kidney, liver and adipose tissue of these ani-
mals while the DNA and RNA content remained unaltered
(Table 2). Streptozotocin injection incremented the pro-
tein content in these three tissues, accompanied in the
case of kidney with an increment of the protein/DNA ratio
and in the case of the liver with an increment of the DNA
content. Treatment with 1,25D3  of streptozotocin-
induced diabetic rats practically did not modify neither
the high values of protein induced by the diabetes in the
three tissues nor the increases in the DNA content in kid-
ney and liver. In addition, this treatment did not alter the
RNA content in any of these three tissues (Table 2).
Insulin receptor mRNA levels in the kidney, liver and 
epididymal adipose tissue
Northern blot assays of kidney (Figure 1, panels A and B),
liver (Figure 1, panels C and D) and epididymal adipose
tissue (Figure 1, panels E and F) from control animals
revealed two major IR mRNA species of approximately 9.5
and 7.5 Kb in size. The relative amounts of the two IR
mRNA species measured as 9.5 Kb/7.5 Kb ratio were: 2.2
± 0.2 in kidney, 1.2 ± 0.2 in liver and 1.1 ± 0.03 in adipose
tissue. Treatment with 1,25D3 to non-diabetic rats did not
affect any of the two IR mRNA species in any of the three
tissues studied (Figure 1, panels A to F). IR mRNA species
were expressed per unit of RNA in view of the observation
(Table 2) that treatment with 1,25D3 to both non-diabetic
and diabetic rats did not alter RNA content per gram of tis-
sue in any of the three tissues. The induction of diabetes
by streptozotocin produced important increments in the
levels of both IR mRNA species in liver and adipose tissue
but not in kidney. In particular, 78% increase correspond-
ing to the 9.5 Kb and 69% to the 7.5 Kb species in liver
(Figure 1, panel D), and 58% increase corresponding to
the 9.5 Kb and 92% increase to the 7.5 Kb species in the
Table 2: Total DNA, RNA and protein content in different tissues from the four groups of rats
Control 1,25D3 STZ STZ + 1,25D3
Kidney
DNA (mg/g) 3.0 ± 0.1 2.8 ± 0.2 3.3 ± 0.5 3.4 ± 0.1ab
Protein(mg/g) 69 ± 2 120 ± 5a 134 ± 33a 153 ± 29ab
Prot/DNA (mg/mg) 18 ± 5 43 ± 2a 41 ± 10a 45 ± 10a
RNA (mg/g) 1.3 ± 0.1 1.6 ± 0.2 1.3 ± 0.3 1.7 ± 0.3
Liver
DNA (mg/g) 1.9 ± 0.2 1.5 ± 0.2 2.9 ± 0.6ab 2.4 ± 0.2ab
Protein(mg/g) 105 ± 19 146 ± 17a 203 ± 27ab 182 ± 15a
Prot/DNA (mg/mg) 52 ± 9 99 ± 11a 67 ± 5 76 ± 3a
RNA (mg/g) 3.9 ± 0.3 3.2 ± 0.4 3.5 ± 0.4 3.8 ± 0.2
Adipose tissue
DNA (mg/g) 0.2 ± 0.06 0.2 ± 0.02 0.3 ± 0.03 0.3 ± 0.04
Protein(mg/g) 5.1 ± 1 8.2 ± 0.8a 7.9 ± 0.5a 6.1 ± 1
Prot/DNA (mg/mg) 24 ± 5 47 ± 6a 25 ± 1b 20 ± 3
RNA (mg/g) 0.1 ± 0.02 0.1 ± 0.01 0.1 ± 0.03 0.1 ± 0.04
Sham-treated rats (Control), rats treated with 1,25D3 [150 IU/Kg (3.75 μg/Kg) one a day, for 15 days] (1,25D3), streptozotocin-induced diabetic rats 
(STZ) and streptozotocin-induced diabetic rats treated with 1,25D3 (STZ+1,25D3).
Values are the mean ± SEM of 4–6 determinations in each group.
a p < 0.05 vs. Control-rats; b p < 0.05 vs. 1,25D3-rats; c p < 0.05 vs. STZ-rats.BMC Molecular Biology 2008, 9:65 http://www.biomedcentral.com/1471-2199/9/65
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Renal, hepatic and adipose IR mRNA levels Figure 1
Renal, hepatic and adipose IR mRNA levels. Insulin receptor (IR) mRNA levels in the kidney (A, B), liver (C, D) and 
epididymal adipose tissue (E, F) of sham-treated rats (Control), rats treated with 1,25D3 [150 IU/Kg (3.75 μg/Kg) one a day, for 
15 days](1,25D3), streptozotocin-induced diabetic rats (STZ) and streptozotocin-induced diabetic rats treated with 1,25D3 
(STZ+1,25D3). On the right, the autoradiograph of a representative Northern blot experiment using the kidney (B), liver (D) 
and adipose tissue (F) of two rats. The sizes of the two major IR mRNA species are shown in the margin. On the left, densito-
metric analysis of three independent Northern blot experiments on kidney (A), liver (C), and adipose tissue (E). IR mRNA spe-
cies were quantified separately, normalized to the respective 28S rRNA values and expressed per unit of RNA as a percentage 
of the values obtained in Control-rats (mean ± SEM). a p < 0.05 vs. Control-rats; b p < 0.05 vs. 1,25D3-rats; and c p < 0.05 vs. STZ-
rats.
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adipose tissue (Figure 1, panel F). Treatment with 1,25D3
to diabetic rats partially prevented the over-expression of
the IR mRNA in the liver (Figure 1, panels C and D) and
adipose tissue (Figure 1, panels E and F) of these animals.
The 9.5 Kb species was particularly decreased in liver and
the 7.5 kb species in the adipose tissue. However, treat-
ment with 1,25D3 to diabetic rats did not affect IR expres-
sion in kidney (Figure 1, panels A and B).
Insulin binding in isolated adipocytes
Insulin binding studies showed that treatment with
1,25D3 to non-diabetic rats did not alter IR number or IR
affinity as reflected by the ED:50 value in adipocytes of
these animals (Figure 2 and Table 3). Streptozotocin
injection produced a 64% decrease in the number of IRs
without altering IR affinity. Treatment with 1,25D3 to
streptozotocin-induced diabetic rats inverted the decrease
in the IR number induced by the diabetes to values not
significantly different from those observed in control adi-
pocytes and without altering IR affinity (Figure 2 and
Table 3).
Given that both the weight of the adipose tissue and the
diameter of the adipocytes were markedly decreased by
the diabetes (Table 3), we also calculated the IR number
per cell surface area (μm2). In these conditions, although
the effect of the diabetes decreasing IR number was some-
what minor (44%), the tendency of 1,25D3 to normalize
the IR number was also evident (Table 3).
Glucose transport in isolated adipocytes
Treatment with 1,25D3 to non-diabetic rats did not alter
basal or insulin-stimulated glucose transport in adi-
pocytes from these animals (Figure 3). The injection of
streptozotocin clearly decreased both basal and insulin-
stimulated glucose transport. The treatment with 1,25D3
to streptozotocin-induced diabetic rats, improved by
107% the decreased basal glucose transport and by 71%
the insulin-stimulated glucose transport in adipocytes
from these diabetic animals (Figure 3).
Computer analysis of DNA sequences in the rat IR gene 
promoter
We performed a computer search of virtual VDRE
sequences in the rat IR gene promoter by homology with
two  consensus  VDRE sequences. The first consensus
(5'GGGTCANNGGGGGCA3') was previously compiled
and reported by us from a series of described functional
VDRE sequences in various 1,25D3-stimulated promoters
[29]. The search with this first consensus  indicated no
sequence identical to this VDRE sequence, and neither
was any sequence found to show 1, 2, or 3 base variations.
Nevertheless, we detected three virtual VDRE sequences
showing a difference of four bases from this consensus: -
249/-235, -637/-623 and -916/-902 (Figure 4, panel A).
Comparison of the 3' half-element of each of these
sequences with the 3' half-element of this first VDRE con-
sensus, indicated complete homology only in the case of
the -916/-902 sequence, and two base variations in the
other two (Figure 4, panel A).
The second computer search of virtual VDREs, now by
homology with the second consensus  VDRE sequence
(5'PuGGTCANNPuPuGTTCA3'), was also performed.
Our consensus and the latter proposed by Colnot et al.
[27], and Haussler et al. [26] have identical 5' half-ele-
ments, but ours contains two GG instead of two TT, in the
3' half-element. The spacers are identical, with a G or Pu
at position 3, which appears to be important in VDR bind-
ing. The results of this computer search by homology with
this second consensus indicated no sequence identical to
this VDRE, and neither was any sequence found to show
1, 2, or 3 base variations. Nevertheless, we detected three
virtual VDRE sequences showing a difference of four bases
from this second consensus: -25/-11, -247/-233 and -881/-
867 (Figure 4, panel A). Of these, the -247/-233 sequence
was in part the same as that of the -249/-235 sequence
detected with the first consensus (Figure 4, panel A). How-
ever, the 3' half-element of this second sequence has only
one base variation instead of two that the first sequence
had (Figure 4, panel A). Therefore, in principle there were
six virtual VDRE sequences (Figure 4, panel A).
Table 3: Insulin binding parameters in epididymal adipocytes from the four groups of rats
Control 1,25D3 STZ STZ + 1,25D3
Insulin receptor number 122000 ± 23000 153000 ± 39000 44000 ± 6000ab 115000 ± 42000c
ED:50 value 3.0 ± 0.4 4.2 ± 1.4 3.7 ± 1.4 4.8 ± 0.9
Adipose tissue weight (g) 3.2 ± 0.2 3.0 ± 0.3 1.6 ± 0.2ab 2.0 ± 0.2a
Adipocyte diameter (μm) 50 ± 1 51 ± 1 39 ± 3ab 40 ± 1ab
Insulin receptor number/μm2 16 ± 3 19 ± 5 9 ± 1ab 23 ± 8
Sham-treated rats (Control), rats treated with 1,25D3 [150 IU/Kg (3.75 μg/Kg) one a day, for 15 days] (1,25D3), streptozotocin-induced diabetic rats 
(STZ) and streptozotocin-induced diabetic rats treated with 1,25D3 (STZ+1,25D3).
Values are the mean ± SEM of 3–9 determinations in each group.
a p < 0.05 vs. Control-rats; b p < 0.05 vs. 1,25D3-rats; c p < 0.05 vs. STZ-rats.BMC Molecular Biology 2008, 9:65 http://www.biomedcentral.com/1471-2199/9/65
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The next step was to check for the possibility of cis-ele-
ments related to these virtual VDRE sequences in the rat IR
gene promoter. Thus, a computer search of AP-1 and AP-
2 sites by homology with the AP-1 site consensus
(5'TGAC/GTCA3') [31], and the AP-2 site consensus
(5'GCCN3GGG3') [32], respectively, was performed.
Exploring the AP-1 sites, we detected two AP-1-like sites
showing a difference of only one base from this consen-
sus: the -374/-368 (5'TGTCTCA3') and the -963/-957
(5'TGAGCCA3'). However, these two sites are neither
adjacent nor overlapped in any of our virtual VDRE
sequences. Nevertheless, as far as we know, this is the first
mention of these AP-1-like sites in the rat IR gene pro-
moter. With respect to the AP-2 sites, we detected seven-
teen AP-2-like sites showing a difference of only one base
from this consensus: -71/-63, -79/-71, -171/-163, -195/-
187, -230/-222, -245/-237, -253/-245, -405/-397, -465/-
457, -480/-472, -545/-537, -634/-626, -635/-627, -642/-
634, -650/-642, -1087/-1079, -1088/-1080. Of these AP-
2-like sites, only seven are included in panel B of the Fig-
ure 4. These were those flanking or overlapping some of
the potential VDRE sequences indicated in panel A of the
Figure 4. Of them, the -230/-222 (1) was located down-
stream, and the -245/-237 (2) and the -253/-245 (3) were
overlapping the virtual VDRE sequences: -249/-235 and -
247/-233, as shown in Figure 4, panel C. Moreover, the
AP-2-like sites: -634/-626 (4) and -635/-627 (5) (Figure 4,
panel B) were overlapping the virtual VDRE sequence: -
637/-623 (Figure 4, panel C), and the AP-2-like sites: -
642/-634 (6) and -650/-642 (7) (Figure 4, panel B) were
located  in tandem upstream of this last virtual VDRE
sequence: -637/-623 (Figure 4, panel C).
Therefore, we postulate as candidate VDRE sequences
overlapped by AP-2-like sites those represented in Figure
4, panel C. One, located between -256 and -219 bp with
three AP-2-like sites, and the other extending from -653
and -620 bp of the rat IR gene promoter with four AP-2-
like sites. Separately or together, these VDRE sequences
could form a locus that may respond to 1,25D3 via activa-
tion of VDR.
Discussion
Effects of treatment with 1,25D3 to non-diabetic rats
Treatment with 1,25D3  to non-diabetic rats increased
body weights but it did not affect any parameter measured
in the plasma or urine of these animals, including the
plasma levels of calcium, phosphorus and 25-hydroxyvi-
tamin D3. Indeed, we did not detect significant differences
in calcium and phosphorus, despite the increases of
approximately 30%. In relation to 25-hydroxyvitamin D3
a number of studies [33] has shown that human serum
values of 25-hydroxyvitamin D3 were maintained within a
normal range across vitamin D supplies from 80 to 1000
Insulin receptor number per cell Figure 2
Insulin receptor number per cell. Insulin receptor 
number in epididymal adipocytes from sham-treated rats 
(Control), rats treated with 1,25D3 [150 IU/Kg (3.75 μg/Kg) 
one a day, for 15 days] (1,25D3), streptozotocin-induced dia-
betic rats (STZ) and streptozotocin-induced diabetic rats 
treated with 1,25D3 (STZ+1,25D3). Values are the mean ± 
SEM of 3–9 determinations in each group. a p < 0.05 vs. Con-
trol-rats; b p < 0.05 vs. 1,25D3-rats; and c p < 0.05 vs. STZ-rats.
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Basal and insulin stimulated glucose transport Figure 3
Basal and insulin stimulated glucose transport. Basal 
and insulin stimulated glucose transport in epididymal adi-
pocytes from sham-treated rats (Control), rats treated with 
1,25D3 [150 IU/Kg (3.75 μg/Kg) one a day, for 15 days] 
(1,25D3), streptozotocin-induced diabetic rats (STZ) and 
streptozotocin-induced diabetic rats treated with 1,25D3 
(STZ+1,25D3). Values are the mean ± SEM of 6–7 determina-
tions within each group. a p < 0.05 vs. Control-rats; b p < 0.05 
vs. 1,25D3-rats; and c p < 0.05 vs. STZ-rats.
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IU daily, indicating the existence of an important homeo-
static control system regulating human 25(OH)D3 serum
concentration. Considering this, in the present study we
hypothesize the existence of a similar counter regulatory
mechanism in the rat. This mechanism could maintain rat
plasma values of 25-hydroxyvitamin D3  within the
observed normal range of 15–19 ng/ml, with vitamin D
supplies of 150 IU daily administered by injection plus
the vitamin D consumed in the diet.
Treatment with 1,25D3 increased the protein content and
the indicator of cell size (protein/DNA) in the kidney,
liver, and adipose tissue of non-diabetic rats, although the
DNA and RNA content remained unaltered. These incre-
Panel A: Computer search of vitamin D response elements (VDREs) in the rat insulin receptor (IR) gene promoter Figure 4
Panel A: Computer search of vitamin D response elements (VDREs) in the rat insulin receptor (IR) gene pro-
moter. Potential VDRE sequences in the rat IR gene promoter were identified by their homology with two consensus VDRE 
sequences using the SEQFIND programme developed in our laboratory. Nucleotides identical to the first VDRE consensus are 
labelled by filled circles (●) and nucleotides identical to the second VDRE consensus are labelled by empty circles (❍). Panel B: 
Computer search of AP-2-like sites in the rat insulin receptor (IR) gene promoter. Potential AP-2-like sites in the rat IR gene 
promoter were identified by their homology with the AP-2 consensus (5'GCCN3GGG3') [32] using the SEQFIND programme. 
We detected 17 AP-2-like sites showing a difference of only 1 base from this consensus. Of these, only 7 AP-2-like sites flanking 
or overlapping the potential VDRE sequences in panel A are shown. Nucleotides identical to the AP-2 consensus are labelled by 
stars ($). Panel C: Candidate VDRE sequences overlapped by AP-2-like sites in the rat insulin receptor gene promoter. 
Nucleotides identical to the first VDRE consensus are labelled by filled circles (●) and nucleotides identical to the second VDRE 
consensus are labelled by empty circles (❍)
5’ G  G  G  T  C  A N  N  G  G  G  G  G  C  A 3’   [29]
(-235) (-249) G  G  G  T  G  A C  C  C  G  G  G  G  T  T
(-623) (-637) C  G  G  G  C  A A  A  G  G  G  G  C  G  A
(-902) (-916) A  A  C   T  C  T T  T  G  G  G  G  G  C  A
5’ Pu G  G  T  C  A N  N  Pu Pu G  T  T  C  A 3’ [26,27]
(-11) (-25) G  G  G  T  C  C C  A  G  C  G  C  T  C  C
(-233) (-247) G  T  G  A  C  C C  G  G  G  G  T  T  G  A
(-867) (-881) G  A  G  T  C  T C  A  G  A  G  T  T  G  T
First consensus
VDRE
Second consensus
VDRE
5’ G  C  C  N  N  N  G  G  G  3’ [32]
(-222) (-230) G  T  C  T  G  C  G  G  G
(-237) (-245) G  A  C  C  C  G  G  G  G
(-245) (-253) G  C  C  T  G  G  G  T  G
(-626) (-634) G  C  A  A  A  G  G  G  G
(-627) (-635) G  G  C  A  A  A  G  G  G
(-634) (-642) G  C  G  A  G  C  G  G  G
(-642) (-650) G  C  G  A  C  T  G  G  G
1
2
3
4
5
6
7
Consensus
AP-2 site
B A
5’  C  G  G  G  C  C  T  G  G  G  T  G  A  C  C  C  G  G  G  G  T   T  G  A  T  A  G  T  C  T  G  C  G  G G  C  C  G  3’ (-219) (-256)
AP-2-like (3) AP-2-like (2) AP-2-like (1)
First VDRE
Second VDRE
5’  G  A  G  G  C  G  A  C  T  G  G  G  C  G  A  G  C  G  G  G  C   A  A  A  G  G  G  G  C  G  A  G  A  A  3’ (-620) (-653)
AP-2-like (7) AP-2-like (6) AP-2-like (4)
First VDRE
AP-2-like (5)
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ments might indicate hypertrophy. However, although
treatment with 1,25D3 increased rat body weights, it did
not particularly augment the weight of these tissues.
Another explanation is that 1,25D3 might cause hyperpla-
sia. Regarding this, conflicting results have been reported
[34,35].
We also observed that treatment with 1,25D3 to non-dia-
betic rats did not affect the expression of any of the two
9.5 and 7.5 Kb IR mRNA species present in kidney, liver,
and adipose tissue. Our group and others have previously
reported the presence of these species and their relative
proportions in rat tissues [21,36]. Since there is only one
rat IR gene, variation in transcript length may reflect alter-
native RNA processing events, such as polyadenylation at
different 3' end sites in the final untranslated exon [37].
In addition, we detected that treatment with 1,25D3 to
non-diabetic rats affected neither the IR number nor the
insulin response in terms of glucose transport in isolated
adipocytes from these animals.
The lack of effects of 1,25D3 on IR expression and insulin
activity in tissues of non-diabetic rats could be related to
the absence of VDR in these tissues. However, both the
VDR protein and VDR mRNA have been detected in the
rat kidney [38,39] and liver [40,41], and while a VDR-like
protein was identified in 3T3-L1 adipose cells [42] VDR
mRNA has been found in rat perirenal adipose tissue and
3T3-L1 adipose cells [43]. Another possibility could be the
absence of regulation of VDR by its ligand in these tissues.
Such lack of regulation has been described in the kidney
[39]. In the liver there are no previous data, while in adi-
pose cells treatment with 1,25D3 led to an increase in VDR
mRNA levels [43] and a decrease in VDR protein [35].
Regarding this and given our previous experience in deter-
mining both VDR protein and VDR mRNA expression and
their regulation by 1,25D3 in human cells [6,7], we deter-
mined the expression of this receptor and its regulation by
1,25D3 at the protein level in the kidney, liver and adipose
tissue of non-diabetic rats. Our results showed a VDR pro-
tein only in the kidney (data not shown). More experi-
ments are necessary to confirm this.
Effects of treatment with 1,25D3 to streptozotocin-
induced diabetic rats
Treatment with 1,25D3 to streptozotocin-induced diabetic
rats increased their body weight, but it did not revert the
hyperglycemia and the hypoinsulinemia provoked by the
streptozotocin. We also detected normal levels of 25-
hydroxyvitamin D3  in streptozotocin-induced diabetic
rats in accordance with other authors [30]. These
unchanged levels of 25-hydroxyvitamin D3 in streptozo-
tocin-induced diabetic rats neither were altered by the
treatment with 1,25D3, possibly due to the postulated
plasma homeostatic control system that could regulate
25-hydroxyvitamin D3 plasma levels also in the absence of
insulin in both groups of diabetic rats. In addition, we
observed increased plasma levels of calcium and phos-
phorus after the treatment with 1,25D3. With regard to
these last parameters, it is known that calcium per se is
important for insulin secretion, as well as for correction of
glucose intolerance [44,45]. Moreover, calcium and phos-
phorus have been described as regulators of VDR in renal
and intestinal tissues [39,46].
Treatment with 1,25D3 to streptozotocin-diabetic rats did
not modify the glycosuria and the ketonuria induced by
the diabetes, but partially decreased the number of leuko-
cytes in urine. This latter effect could be due to the broadly
reported anti-inflammatory effects of 1,25D3 and/or to a
possible anti-proliferative effect of this hormone, as
observed by our group and others in cell culture [6,33].
With respect to tissue effects of 1,25D3 in streptozotocin-
induced diabetic rats, we observed the permanence of
high protein and DNA content values induced by the dia-
betes, accompanied by slight increases of the protein/
DNA ratio values in the kidney and liver, but not in the
adipose tissue. This suggests a certain hypertrophy pro-
duced by the action of 1,25D3 in these two tissues. How-
ever, although treatment with 1,25D3 to streptozotocin-
diabetic rats increased rat body weights, it did not increase
the weight of the kidney, liver or adipose tissue. The other
explanation, hyperplasia, has conflicting results [33,34].
The induction of diabetes by streptozotocin did not affect
IR mRNA species in the kidney. This finding was not in
accord with previous results of increased renal IR mRNA
levels, quantified by slot blot, in a similar rat model [22].
This may reflect the failure to alter VDR number in the
kidney of streptozotocin-diabetic rats [34]. The treatment
with 1,25D3 to streptozotocin-induced diabetic rats nei-
ther affected IR mRNA species in the kidney.
Contrarily, streptozotocin produced an important incre-
ment in the levels of both IR mRNA species in liver. These
findings agree with previous results of increased IR mRNA
levels quantified by slot blot [22], Northern blot analysis
[21,47] and increased IR gene transcription [21] in the
liver of streptozotocin-induced diabetic rats. Streptozo-
tocin also increased the levels of both IR mRNA species in
the adipose tissue. This increment represents the first
demonstration of an in vivo regulation of IR mRNA levels
in the adipose tissue of streptozotocin-induced diabetic
rats.
In addition, we observed that the treatment with 1,25D3
to streptozotocin-induced diabetic rats partially prevented
the over-expression of IR mRNA induced by the diabetesBMC Molecular Biology 2008, 9:65 http://www.biomedcentral.com/1471-2199/9/65
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in the liver and adipose tissue of these animals. The 9.5 Kb
IR mRNA species was particularly decreased by 1,25D3 in
the liver, and the 7.5 Kb species in the adipose tissue.
Therefore, these results provide the first demonstration of
an in vivo tissue-specific regulation of rat IR mRNA levels
by 1,25D3 in streptozotocin-induced diabetic rats.
A role for VDR in such genomic actions of 1,25D3 in liver
and adipose tissue is possible, although to our knowledge
the regulation of VDR by 1,25D3 has not yet been studied
in these tissues of streptozotocin-diabetic rats.
The correction by 1,25D3 of the over-expression of IR
expression at the RNA level in the liver and adipose tissue
of streptozotocin-diabetic animals could represent a ben-
eficial fact of amelioration of the diabetes. In this sense,
other facts of amelioration of diabetes were the almost
normalization of the number of IRs in adipocytes of strep-
tozotocin-diabetic animals treated with 1,25D3, without
alterations in receptor affinity, and the improvement of
both basal and insulin-stimulated glucose transport in
adipocytes of these diabetic animals treated with 1,25D3.
The present in vivo results do not allow to determine
whether the prevention by 1,25D3 of the over-expression
of IR mRNA induced by the diabetes in liver and adipose
tissue of streptozotocin-diabetic animals is due to tran-
scriptional and/or post-transcriptional regulation. Never-
theless, our previous in vitro results demonstrated that
1,25D3 increased IR mRNA levels via mechanisms involv-
ing direct transcriptional activation of the human IR gene
[5-7]. Moreover, we identified an active VDRE in the
human IR gene promoter that accounted for the transcrip-
tional induction of this gene by 1,25D3 in U-937 cells
[29].
Therefore, in support of the possible participation of a
transcriptional regulation by 1,25D3 in the present in vivo
processes, we have detected by computer search in the rat
IR gene promoter two candidate VDREs overlapped by
various AP-2-like sites. One VDRE is located between -256
and -219 bp, while the other extends from -653 and -620
bp of the rat IR gene promoter (Figure 4, panel C). Indi-
vidually or in conjunction, these potential VDREs could
form a locus that may respond to 1,25D3 via activation of
VDR. This locus may mediate the cross-talk between vita-
min D and insulin signalling, although this remains to be
determined.
Conclusion
The present results indicate that while treatment with
1,25D3 had practically no effect on non-diabetic rats, the
same treatment in streptozotocin-induced diabetic rats
corrected in part the over-expression of the IR gene in liver
and adipose tissue, although it did not revert the hyperg-
lycemia, hypoinsulinemia, glycosuria or ketonemia of
these diabetic animals. At the same time, it produced nor-
malization of the IR number without alterations in the
receptor affinity, but with an improvement of the insulin
response in terms of glucose transport in adipocytes of
these diabetic animals. These genomic actions of 1,25D3
could represent beneficial facts of amelioration of diabe-
tes via mechanisms, possibly involving direct transcrip-
tional activation of the rat IR gene. A computer search in
the rat IR promoter revealed the existence of two candi-
date vitamin D response element (VDRE) sequences,
located at -256/-219 bp and -653/-620 bp and overlapped
by three and four AP-2-like sites respectively. These candi-
date VDREs may respond to 1,25D3 via activation of the
vitamin D receptor, although this remains to be investi-
gated.
Methods
Animals and sampling
Four groups of male Wistar rats weighing 200–220 g at the
onset were used in this study. They were kept under stand-
ard conditions of light and temperature and given free
access to tap water and standard laboratory chow (Panlab,
A04) containing 8.8 mg/g of calcium, 5.9 mg/g of phos-
phorus and 1.5 IU/g of vitamin D. The first group com-
prised of non-diabetic rats receiving sham-treatments
during the 15 days of the experimental period (Control-
rats). The second group included non-diabetic rats i.p.
injected with 1,25D3 (Calcijex, Abbot) [150 IU/Kg (3.75
μg/Kg) one a day, for 15 days] (1,25D3-rats). The third
group consisted of rats rendered diabetic by a single injec-
tion of streptozotocin (Sigma) [65 mg/kg] on the 8th day
of the 15-day period (STZ-rats). Finally, the fourth group
comprised of rats rendered diabetic by streptozotocin on
the 8th day, and i.p. injected with 1,25D3 [150 IU/Kg
(3.75 μg/Kg) one a day, for 15 days] (STZ+1,25D3-rats).
The National Guide for the Care and Use of Laboratory
Animals was strictly followed during this study.
Urine samples were collected before decapitation without
anaesthesia and trunk blood samples were recovered for
plasma measurements. On sacrifice, the kidney, liver and
epididymal adipose tissue were immediately removed,
individually packed and frozen in liquid nitrogen for
nucleic acid and protein determinations. Isolated adi-
pocytes were obtained from fresh epididymal adipose tis-
sue for insulin binding and insulin activity assays.
Analytical methods
Different parameters in urine were measured using the
Combur Test (Roche). Plasma insulin levels were deter-
mined by radioimmunoassay using rat insulin as stand-
ard. Plasma concentrations of glucose, 25-
hydroxyvitamin D3, calcium, phosphorus and proteins
were estimated using commercially available techniques.BMC Molecular Biology 2008, 9:65 http://www.biomedcentral.com/1471-2199/9/65
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The total DNA and RNA contents of the homogenates
from individual tissues were estimated by spectrofluor-
ometry. The protein content was determined by the Brad-
ford method.
RNA blot assays
For Northern blot assays, RNA samples (40 μg) of kidney,
liver and epididymal adipose tissue, were denatured, elec-
trophoresed in 1.1% agarose-formaldehyde gels and blot-
ted onto nylon membranes [36]. Ethidium bromide
staining of the 28S and 18S ribosomal RNAs was routinely
checked before blotting as a control of sample loading
and after blotting as a control of RNA transfer. RNA blots
were prehybridized, hybridized with excess [32P]-labelled
probe (the 0.98-Kb rat IR specific EcoR1 fragment of the
p16 clone, gift from Prof. Goldstein), washed under strin-
gent conditions and finally autoradiographed, as
described previously [36]. The autoradiographs were
scanned with a laser densitometer and the readings nor-
malized with the respective amounts of 28S rRNA, as
revealed by ethidium bromide.
Insulin binding assays
Binding assays were carried out as described previously
[48]. In brief, isolated adipocytes (0.25 × 106 cells/ml)
were incubated at 30°C for 30 min in 400 μl Krebs-Hepes
buffer pH 7.6 with mono-[125I]-insulin (0.2 × 10-9 M)
(NEN Life Sciences), in the presence or absence of increas-
ing concentrations (0.2 × 10-10 to 0.5 × 10-7 M) of unla-
belled insulin (Sigma). Non-specific binding was
determined in the presence of 1 × 10-7 M unlabelled insu-
lin and subtracted from each point. The adipocyte
number was determined with a Neubauer-type hemocy-
tometer and cell viability (assessed by 0.2% trypan blue
exclusion) was greater than 90%. Measurements of the
cell diameter were also performed. The data were analysed
by the Scatchard method using the LIGAND program of
Munson and Rodbard [49].
Glucose transport determinations
Glucose transport was measured in isolated adipocytes by
determining the uptake of D-[14C(U)]-glucose (NEN Life
Sciences) at trace concentrations using our modification
of the method of Kashiwagi et al. [50]. This method is
based on the premise that glucose uptake provides a meas-
ure of glucose transport when studies are carried out at
very low glucose concentrations. In brief, 0.25 × 106 adi-
pocytes/ml were incubated with 5 × 10-7 M D-[14C(U)]-
glucose for 1 h at 37°C in the presence and absence of a
concentration of insulin (10-8 M) that gave maximal glu-
cose transport in earlier experiments [6]. Assays were
stopped by washing the cells with ice-cold PBS. The cells
were solubilized in 0.5% SDS and 0.1 N NaOH and the
associated radioactivity was counted.
Computer analysis of DNA sequences in the rat IR gene 
promoter
The identification of virtual VDRE sequences in the Rattus
norvegicus partial IR promoter [GenBank:AJ006071] was
carried out by homology with two consensus  VDRE
sequences using the SEQFIND programme developed in
our laboratory and previously employed in the computer
analysis of various DNA sequences including VDREs [29].
The first consensus  (5'GGGTCANNGGGGGCA3') had
been compiled and reported by us from a series of
described functional VDRE sequences in various 1,25D3-
stimulated promoters [29]. The second consensus VDRE
sequence (5'PuGGTCANNPuPuGTTCA3') had been pro-
posed by Colnot et al. [27], and Haussler et al. [26]. The
presence of AP-1 and AP-2 sites flanking or overlapping
the potential VDREs were identified by their homology
with the AP-1 site consensus (5'TGAC/GTCA3') [31] and
the AP-2 site consensus  (5'GCCN3GGG3') [32] respec-
tively, also using the SEQFIND programme.
Statistical analysis
Unless otherwise indicated, the data are expressed as the
mean ± SEM. A comparison between the groups was car-
ried out using the two-tailed, unpaired Student t-test and/
or ANOVA comparison, as appropriate. Differences were
considered statistically significant when p < 0.05.
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